Clinical trials: Conversion Disorder
Epilepsy
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy patients when switching from LAMICTAL immediate-release to extended-release and vice versa.
- Trial name
- NCT00264615
- Testing
- lamotrigine extended-release
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Biliary Tract Diseases
Cholecystitis in Villavicencio Hospitals
Background: Acute cholecystitis is a frequent cause of visits to the emergency ward. The complications of delays in attention and surgical therapy are substantial and should be considered to prevent them timely.
- Trial name
- NCT06048575
- Testing
- Cholecystectomy
- Where
- Colombia
- Volunteers
- 609 people
- Sponsor
- Hospital Departamental de Villavicencio
Pigment Dispersion Syndrome
Pigment Dispersion Syndrome: Natural History and Possible Protective Effect of a YAG Laser Iridotomy
STUDY AIMS 1. To determine the 10-year conversion rate from pigment dispersion syndrome (PDS) to pigmentary glaucoma (PG) 2. To evaluate the possible protective effect of a Yag-laser iridotomy
- Trial name
- NCT01053416
- Testing
- Yag laser iridotomy
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- University of Parma
Anemia of Chronic Kidney Disease
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
This study will assess the safety and efficacy of once daily dosing of vadadustat for the treatment of pediatric participants with anemia of Chronic Kidney Disease (CKD) after conversion from an Erythropoiesis Stimulating Agent…
- Trial name
- CONVERSION (NCT05082571)
- Testing
- vadadustat
- Where
- United States
- Sponsor
- Akebia Therapeutics
Severe Malaria, Uncomplicated Malaria
Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. A new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion…
- Conditions
- Severe Malaria, Uncomplicated Malaria, Asyptomatic Plasmodium Infection
- Trial name
- IMMETASEX (NCT06064591)
- Where
- 3 sites in Belgium, Burkina Faso and 1 more
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium